If you have been reading about Aseptic technique and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Solvent selection depends on the peptide's charge, hydrophobicity, and intended application. Many lyophilized peptides dissolve readily in water, while others require a small amount of a miscible organic solvent, a dilute acid, or a dilute base before aqueous dilution. A buffer may be used when a stable pH range is known, but adding buffer salts can also promote aggregation or precipitation. Dissolution should be observed rather than assumed, because a clear solution does not prove that the peptide is monomeric or fully active. The order of solvent addition and the final volume matter for achieving the intended concentration.
Once reconstituted, a peptide solution is generally less stable than the dry powder. Hydrolysis, oxidation, aggregation, and microbial growth can change the preparation over time, so storage temperature and duration are practical concerns. Dividing a solution into single-use aliquots before freezing can reduce repeated freeze-thaw cycles, which may otherwise cause precipitation or loss of activity. The optimal storage conditions vary by peptide, and no single rule applies to all sequences. Records of solvent, concentration, date, and storage history help maintain traceability. Studies often report stability under defined conditions rather than universal shelf lives.
Reconstitution is the process of dissolving a lyophilized peptide powder in a suitable liquid to produce a solution for laboratory or clinical use. The dry powder is typically a porous cake or fluffy solid formed by freeze-drying an aqueous or mixed-solvent preparation. Adding solvent restores the peptide to a dissolved state, but the result is not necessarily identical to the original pre-lyophilization solution. Factors such as pH, ionic strength, temperature, and the peptide's sequence influence how completely and quickly dissolution occurs. The term is distinct from dilution, which lowers concentration without changing the physical state of an already dissolved material.
Documentation supports reproducibility and traceability. Records often include lot number, solvent composition, final concentration, preparation date, and storage location. Such details help distinguish procedural variation from actual sample instability. Questions remain about how best to predict long-term stability from short-term accelerated studies, because peptide degradation pathways differ widely. For many peptides, the relationship between in vitro solution stability and biological behavior is incompletely understood and is an active area of research.
After reconstitution, a peptide solution is typically stored under conditions that limit degradation. Cool temperatures slow hydrolysis and oxidation, while freezing can preserve samples for longer periods. Repeated freeze-thaw cycles may promote aggregation or precipitation, so aliquoting before freezing is a common laboratory practice. The optimal storage temperature depends on the peptide sequence, buffer composition, and expected duration. Solutions containing oxidizable residues may benefit from inert gas overlays or antioxidants, though compatibility with the specific peptide must be considered.
| Property | Value | Notes |
|---|---|---|
| Physical state before reconstitution | Lyophilized powder or cake | Appearance varies from fluffy to compact; not a solution. |
| Common solvent | Sterile or ultrapure water | Many peptides dissolve, but solubility is sequence-dependent. |
| Alternative solvent | Dilute acetic acid or acetonitrile/water | Used for hydrophobic or basic peptides; compatibility varies. |
| Typical storage after reconstitution | 2–8 °C short term; −20 °C or below for aliquots | Stability is peptide-specific; avoid repeated freeze-thaw. |
| Common analytical method | Reverse-phase HPLC | Assesses purity and concentration; mass spectrometry confirms identity. |
Quality control of reconstituted peptides combines visual inspection with instrumental analysis. A clear solution does not prove correct identity or purity, and a cloudy solution does not always indicate failure. Reverse-phase high-performance liquid chromatography can separate the peptide from related impurities, while mass spectrometry confirms molecular mass and detects modifications. pH measurement and osmolality checks provide additional information about the solution environment, and documentation of lot number, solvent, and storage history supports traceability.
After a peptide is reconstituted, handling practices affect its chemical and physical stability over time. Aqueous solutions can support microbial growth unless they are prepared with aseptic technique or contain preservatives. Container material matters because peptides can adsorb to glass or plastic surfaces, reducing the amount available in solution. Repeated transfers increase exposure to air and potential contaminants, and temperature fluctuations can accelerate degradation. These factors are separate from the peptide's intrinsic sequence-based stability.
The choice of solvent depends on the peptide's sequence, charge, and solubility profile. Water is common for hydrophilic peptides, while aqueous mixtures containing acetonitrile, methanol, or a small amount of acid may be needed for hydrophobic or basic sequences. Adding the liquid to the powder, rather than the reverse, can reduce clumping and improve wetting. Gentle mixing or brief vortexing may help, but vigorous agitation can create foam and shear sensitive structures. Complete dissolution is judged by a clear solution with no visible particles.
Buffer components and ionic strength affect how a peptide dissolves and remains in solution. Some sequences require a defined pH range to avoid precipitation or aggregation, while others tolerate pure water. The optimal conditions are often determined empirically because solubility cannot be predicted reliably from sequence alone. Even when a peptide dissolves, the resulting solution may contain aggregates that are not visible to the eye. Analytical methods such as reversed-phase high-performance liquid chromatography and mass spectrometry are used to confirm identity and purity after reconstitution.
Peptide reconstitution is the process of dissolving a dried peptide preparation in a liquid solvent to form a solution. Many peptides are supplied as lyophilized powders because removing water improves stability during shipping and storage. The dried material may appear as a cake, flake, or loose powder depending on the manufacturing and drying method. Reconstitution restores the peptide to a liquid state so that it can be further diluted, analyzed, or handled in laboratory workflows. The term is distinct from dilution, which lowers concentration after a solution already exists.
After reconstitution, peptide solutions are generally less stable than lyophilized powders, and hydrolysis, oxidation, deamidation, and aggregation can occur in solution. Stability depends on peptide sequence, concentration, pH, buffer composition, temperature, light exposure, and dissolved oxygen. Many research protocols store reconstituted solutions at 4 °C for short periods or at -20 °C or -80 °C for longer periods. Repeated freeze-thaw cycles can promote aggregation and loss of activity. The optimal storage condition is peptide-specific and often determined empirically rather than predicted from sequence alone.
Quality control after reconstitution often includes visual inspection for particulates, pH measurement, and concentration determination by ultraviolet absorbance at 280 nm when aromatic residues are present. Reverse-phase high-performance liquid chromatography can assess purity and reveal degradation peaks. Mass spectrometry confirms molecular identity and detects modifications such as oxidation or truncation. Size-exclusion chromatography can quantify aggregates and oligomers. These methods are established for many peptides but may require optimization for hydrophobic or chemically modified sequences.
Lyophilization removes water from a peptide solution under vacuum, leaving a porous cake or a loose powder. The dry form often improves stability during shipping and storage because water-mediated degradation slows. Reconstitution reverses the process by adding a solvent so peptide molecules hydrate and enter solution. Complete dissolution depends on peptide sequence, purity, salt form, and any excipients present. Some lyophilized powders dissolve quickly, while others form haze, gels, or persistent particles.
Solvent selection affects pH, ionic strength, and preservative content in the final liquid. Sterile water and bacteriostatic water containing benzyl alcohol are common in laboratory settings. Buffer systems may be used when a peptide is sensitive to pH shifts during dissolution. Acidic or basic conditions can change the net charge of ionizable groups and therefore solubility. Organic cosolvents are sometimes added for hydrophobic sequences, though they can also promote unfolding or aggregation.
During reconstitution, solvent penetrates the powder, breaks interparticle contacts, and solvates polar and nonpolar groups. Gentle mixing or swirling can speed dissolution, while vigorous shaking may introduce foaming and surface denaturation. Aggregation becomes more likely when the peptide concentration exceeds its solubility or when the pH is near the isoelectric point. The link between a specific reconstitution method and long-term stability is not fully predictable from sequence alone. How excipients, container surfaces, and residual moisture influence aggregation remains an open question.
Activated carbon can be manufactured from carbonaceous material, including coal (bituminous, subbituminous, and lignite), peat, wood, or nutshells (e.g., coconut). The manufacturing process consists of two phases: carbonization and activation. The carbonization process includes drying and then heating to separate by-products, including tars and other hydrocarbons from the raw material, as well as to drive off any gases generated. The process is completed by heating the material over 400 °C (750 °F) in an oxygen-free atmosphere that cannot support combustion. The carbonized particles are then "activated" by exposing them to an oxidizing agent, usually steam or carbon dioxide, at high temperature. This agent burns off the pore-blocking structures created during the carbonization phase, and so they develop a porous, three-dimensional graphite lattice structure. The size of the pores developed during activation is a function of the time that they spend in this stage. Longer exposure times result in larger pore sizes. The most popular aqueous phase carbons are bituminous based because of their hardness, abrasion resistance, pore size distribution, and low cost, but their effectiveness needs to be tested in each application to determine the optimal product. Activated carbon is used for adsorption of organic substances and non-polar adsorbates and it is also usually used for waste gas (and waste water) treatment. It is the most widely used adsorbent since most of its chemical (e.g. surface groups) and physical properties (e.g.
=== Tracking of Fusion Proteins === Many different fusion proteins have been created using EosFP and its engineered variants. These fusion proteins allow for the tracking of proteins within living cells while retaining complex biological functions like protein-protein interactions and protein-DNA interactions. Eos fusion constructs include those with recombination signal-binding protein (RBP) and cytokeratin. Studies have shown that it is favourable to attach the protein of interest to the N-terminal side of the EosFP label. These fusion constructs have been used to visualize nuclear translocation with androgen receptors, dynamics of the cytoskeleton with actin and vinculin and intranuclear protein movement with RBP.
== Chromatography == One of the main reasons to use response factors is to compensate for the irreproducibility of manual injections into a gas chromatograph (GC). Injection volumes for GCs can be 1 microliter (μL) or less and are difficult to reproduce. Differences in the volume of injected analyte leads to differences in the areas of the peaks in the chromatogram and any quantitative results are suspect. To compensate for this error, a known amount of an internal standard (a second compound that does not interfere with the analysis of the primary analyte) is added to all solutions (standards and unknowns). This way if the injection volumes (and hence the peak areas) differ slightly, the ratio of the areas of the analyte and the internal standard will remain constant from one run to the next. This comparison of runs also applies to solutions with different concentrations of the analyte. The area of the internal standard becomes the value to which all other areas are referenced. Below is the mathematical derivation and application of this method. Consider an analysis of octane (C8H18) using nonane (C9H20) as the internal standard. The 3 chromatograms below are for 3 different samples.
=== Morphological variation === Plants exhibit natural variation in their form and structure. While all organisms vary from individual to individual, plants exhibit an additional type of variation. Within a single individual, parts are repeated which may differ in form and structure from other similar parts. This variation is most easily seen in the leaves of a plant, though other organs such as stems and flowers may show similar variation. There are three primary causes of this variation: positional effects, environmental effects, and juvenility.
=== Sources === Cleveland Clinic. "LADA Diabetes." Cleveland Clinic, https://my.clevelandclinic.org/health/diseases/lada-diabetes. Accessed 9 Apr. 2026. Diabetes UK. "Latent Autoimmune Diabetes (LADA)." Diabetes UK, https://www.diabetes.org.uk/about-diabetes/other-types-of-diabetes/latent-autoimmune-diabetes. Accessed 9 Apr. 2026. Eisenbarth, George S., ed. (2010). Immunoendocrinology: Scientific and Clinical Aspects. Contemporary Endocrinology. Humana Press. ISBN 978-1-603-27477-7. Flynn, John A.; Michael J. Choi; L. Dwight Wooster, eds. (2013). Oxford American Handbook of Clinical Medicine. Oxford American Handbooks in Medicine. Oxford University Press. ISBN 978-0-195-18849-3. HealthNormal. "Latent Autoimmune Diabetes in Adults." HealthNormal, https://www.healthnormal.com/latent-autoimmune-diabetes-in-adults/. Accessed 9 Apr. 2026. "Latent Autoimmune Diabetes in Adults: Current Status and New Horizons." SN Comprehensive Clinical Medicine, 2025, https://link.springer.com/article/10.1007/s42399-025-02003-1. Accessed 9 Apr. 2026. "Management of Latent Autoimmune Diabetes in Adults." Diabetes, vol. 69, no. 10, 2020, https://diabetesjournals.org/diabetes/article/69/10/2037/16062. Accessed 9 Apr. 2026. Munden, Julie, ed. (2006). Diabetes Mellitus: A Guide to Patient Care. Lippincott Williams & Wilkins. ISBN 978-1-58255-732-8. Haskins, Jacqueline. Kickass Healthy LADA: How to Thrive with Latent Autoimmune Diabetes in Adults. Hachette Go (2023). ISBN 9780306830730.
Sources: en.wikipedia.org
=== Ben Cousins === Ben Cousins played for the West Coast Eagles and Richmond Football Club in his 12 years of playing AFL. On 16 October 2007, Cousins was arrested in Northbridge, Perth, after police had pulled his vehicle over "due to the manner of his driving". Police searched his car and found quantities of prohibited drugs. Cousins was then sacked by West Coast after serious breaches of his contract with them. In 2009, Cousins joined Richmond to continue his AFL career, but on 12 April Cousins and three other Richmond players were suspended by the club after a drunken altercation in a Sydney hotel. Although Cousins was not intoxicated it was ruled that he had not acted responsibly leading to his suspension for 1 week. A few months later in July, Cousins was admitted to hospital after a severe reaction to the prescribed sleeping pills he had taken. This incident led to the debate of whether legal stimulants (such as caffeine) and legal sedatives (such as sleeping pills) could be used by athletes. The Premier of Victoria, John Brumby, disapproved of their use within sporting events.
== Medical uses == In the US, crisaborole is indicated for topical treatment of mild to moderate atopic dermatitis in people three months of age and older. In the EU, crisaborole was authorized for treatment of mild to moderate atopic dermatitis in people two years of age and older with ≤ 40% body surface area (BSA) affected.
== Historical timeline == 1895 Wilhelm Conrad Röntgen discovers X-rays ("bremsstrahlung", from German for radiation produced by deceleration) 1896 Antoine Henri Becquerel discovers natural radioactivity; Minck proposes the therapeutic use 1904 Samuel Prescott describes the bactericide effects Massachusetts Institute of Technology (MIT) 1906 Appleby & Banks: UK patent to use radioactive isotopes to irradiate particulate food in a flowing bed 1918 Gillett: U.S. Patent to use X-rays for the preservation of food 1921 Schwartz describes the elimination of Trichinella from food 1930 Wuest: French patent on food irradiation 1943 MIT becomes active in the field of food preservation for the U.S. Army 1951 U.S. Atomic Energy Commission begins to co-ordinate national research activities 1958 World first commercial food irradiation (spices) at Stuttgart, Germany 1963 FDA approves food irradiation. NASA begins irradiating astronaut food items to prevent food borne illness during space missions.
The West Coast exhibition site opened on 22 June 2006 at the Tropicana Resort and Casino Las Vegas. As of June 2009, BODIES... The Exhibition is showing at the Ambassador Theatre in Dublin, Ireland. The exhibition was in Istanbul, Turkey, until the end of March 2011. Plastination galleries are offered in several college medical schools, including the University of Michigan (which Michigan Daily reported possessed the United States' largest such lab in 2007), Vienna University, and the JSS Medical Collegem Gunther von Hagens maintains a permanent exhibition of plastinates and plastination at the Plastinarium in Guben, Germany.
== History == Historical descriptions of possible PMOS symptoms date to ancient Greece, where Hippocrates described women with "thick, oily skin and absence of menstruation." The earliest known description of what is now recognized as PMOS dates from 1721 in Italy, which described "Young married peasant women, moderately obese and infertile, with two larger than normal ovaries, bumpy, shiny and whitish, just like pigeon eggs". Polycystic ovaries were likely first formally described in 1844 by the French doctor Achille Chereau. In 1935, American gynecologists Irving F. Stein and Michael L. Leventhal published a report linking polycystic ovaries to hirsutism, infertility, and lack of periods. The report also hypothesised that PMOS results from endocrine dysfunction, initiating research into its hormonal causes and giving rise to the term Stein–Leventhal syndrome. By the 1980s, the metabolic side of PMOS started to be studied, before the start of genetics research in the 1990s.
Sources: en.wikipedia.org
It means adding liquid to a lyophilized peptide powder so it dissolves into solution. The dry powder is not a finished liquid product, and the resulting concentration depends on the volume added. Complete dissolution should be visually confirmed before use.
Some peptides have hydrophobic regions or strong charge interactions that make water a poor solvent alone. A small amount of organic solvent, acid, or base may be needed before aqueous dilution. The appropriate approach depends on sequence and should be based on documented compatibility.
No. Solutions can degrade through hydrolysis, oxidation, aggregation, and microbial growth, and stability varies widely by peptide. Storage at reduced temperature and avoidance of repeated freeze-thaw cycles are common laboratory practices. Specific shelf lives are determined by stability testing, not by a general rule.
Short-term storage is often at refrigerated temperatures, while longer storage may use freezing. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation. Container material and headspace can also affect stability.